{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:53:27Z","timestamp":1762955607006},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gaceta Sanitaria"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.gaceta.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T21:06:44Z","timestamp":1472504804000},"page":"35-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Desprescripci\u00f3n de tratamientos de larga duraci\u00f3n con bisfosfonatos para la osteoporosis en atenci\u00f3n primaria en el Pa\u00eds Vasco"],"prefix":"10.1016","volume":"31","author":[{"given":"Arritxu","family":"Etxeberria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josune","family":"Iribar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacia","family":"Idarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Mozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Vrotsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Belzunegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantxa","family":"Lekuona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gaceta.2016.07.003_bib0110","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis \u2013 for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0120","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0130","unstructured":"Bisfosfonatos y riesgo de fracturas at\u00edpicas de f\u00e9mur. Nota informativa de la AEMPS. MUH (FV) \/04\/2011. Disponible en: https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2011\/NI-MUH_04-2011.htm"},{"key":"10.1016\/j.gaceta.2016.07.003_bib0135","unstructured":"Departamento de Sanidad-Osakidetza. Grupo de trabajo de la osteoporosis. Recomendaciones a seguir tras 2 a\u00f1os de tratamiento con teriparatida (Forsteo\u00ae) y tras 5 a\u00f1os de tratamiento con bisfosfonatos. Disponible en: https:\/\/www.osakidetza.eus\/sites\/Intranet\/es\/referencia-documental\/Documentos%20compartidos\/Asistencia%20Sanitaria\/Farmacia\/Osteoporosis_Recomendaciones.pdf"},{"key":"10.1016\/j.gaceta.2016.07.003_bib0140","unstructured":"Grupo de Trabajo de Osteoporosis Comarca Gipuzkoa-Hospital Donostia-Cl\u00ednica Asunci\u00f3n. Documento de apoyo. Revisi\u00f3n de los tratamientos con bisfosfonatos tras 5 a\u00f1os de tratamiento: aclaraciones a las recomendaciones del Departamento de Salud-Osakidetza. Disponible en: https:\/\/donostialdea.osakidetza.eus\/es\/referencia-documental\/Documentos%20compartidos\/Salud\/Farmacia\/Polimedicacion_Prescripcion_Prudente\/Proyectos_Farmacia\/2_2_Texto_Deprescripcion_Bisfosfonatos.pdf"},{"key":"10.1016\/j.gaceta.2016.07.003_bib0145","first-page":"CD003030","article-title":"Continuing education meetings and workshops: effects on professional practice and health care outcomes","author":"Forsetlund","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0304-4858(10)70024-X","article-title":"Consumidores, prescripci\u00f3n y prescriptores de f\u00e1rmacos para la osteoporosis","volume":"107","author":"Idarreta","year":"2010","journal-title":"Gac Med Bilbao."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0140-6736(93)92244-N","article-title":"Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations","volume":"342","author":"Grimshaw","year":"1993","journal-title":"Lancet."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0160","doi-asserted-by":"crossref","first-page":"e002084","DOI":"10.1136\/bmjopen-2012-002084","article-title":"Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study","volume":"3","author":"Erviti","year":"2013","journal-title":"BMJ Open."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/fampra\/cmu088","article-title":"Increased risk for atypical fractures associated with bisphosphonate use","volume":"32","author":"Lee","year":"2015","journal-title":"Fam Pract."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0170","doi-asserted-by":"crossref","first-page":"h2088","DOI":"10.1136\/bmj.h2088","article-title":"Overdiagnosis of bone fragility in the quest to prevent hip fracture","volume":"350","author":"Jarvinen","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0175","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"New Engl J Med."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/11599100-000000000-00000","article-title":"Impact of safety-related regulatory action on clinical practice","volume":"35","author":"Piening","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0185","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","article-title":"Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review","volume":"50","author":"Dusetzina","year":"2012","journal-title":"Med Care."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0190","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.2012.262","article-title":"When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines","volume":"93","author":"Reber","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.medcli.2012.10.025","article-title":"Variabilidad en las recomendaciones para el abordaje cl\u00ednico de la osteoporosis","volume":"142","author":"Sanf\u00e9lix-Genov\u00e9s","year":"2014","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1210\/jc.2013-3448","article-title":"Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain","volume":"99","author":"Hurtado","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.gaceta.2016.07.003_bib0205","series-title":"XXXII Congreso de la Sociedad Espa\u00f1ola de Medicina de Familia y Comunitaria","article-title":"Gu\u00edas de osteoporosis m\u00e1s reconocidas en la pr\u00e1ctica cl\u00ednica. Repercusi\u00f3n poblacional en la decisi\u00f3n de tratar","author":"Sanf\u00e9lix-Genov\u00e9s","year":"2012"},{"key":"10.1016\/j.gaceta.2016.07.003_bib0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-5908-4-67","article-title":"A theory of organizational readiness for change","volume":"4","author":"Weiner","year":"2009","journal-title":"Implement Sci."}],"container-title":["Gaceta Sanitaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911116301601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911116301601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T18:59:31Z","timestamp":1536433171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213911116301601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0213911116301601"],"URL":"https:\/\/doi.org\/10.1016\/j.gaceta.2016.07.003","relation":{},"ISSN":["0213-9111"],"issn-type":[{"value":"0213-9111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Desprescripci\u00f3n de tratamientos de larga duraci\u00f3n con bisfosfonatos para la osteoporosis en atenci\u00f3n primaria en el Pa\u00eds Vasco","name":"articletitle","label":"Article Title"},{"value":"Gaceta Sanitaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gaceta.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SESPAS. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}